ENCISION INC — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that ENCISION INC filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $6.56M | Jul 10, 2025 |
| FY2025 | Mar 31, 2024 | $6.59M | Jul 10, 2025 |
| FY2024 | Mar 31, 2023 | $7.35M | Jul 15, 2024 |
| FY2023 | Mar 31, 2022 | $7.67M | Jun 29, 2023 |
| FY2022 | Mar 31, 2021 | $7.54M | Jul 13, 2022 |
| FY2021 | Mar 31, 2020 | $7.67M | Jun 23, 2021 |
| FY2020 | Mar 31, 2019 | $8.80M | Jun 12, 2020 |
| FY2019 | Mar 31, 2018 | $8.75M | Jun 14, 2019 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Mar 31, 2018 | $8.75M | Jun 14, 2018 |
| FY2018 | Mar 31, 2017 | $8.87M | Jun 14, 2018 |
| FY2017 | Mar 31, 2016 | $9.34M | Jun 14, 2017 |
| FY2016 | Mar 31, 2015 | $9.67M | Jun 14, 2016 |
| FY2015 | Mar 31, 2014 | $10.55M | Jun 19, 2015 |
| FY2014 | Mar 31, 2013 | $11.77M | Jun 26, 2014 |
| FY2012 | Mar 31, 2012 | $12.99M | Jun 28, 2013 |
| FY2011 | Mar 31, 2011 | $11.62M | May 16, 2012 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $3.51M | Jul 10, 2025 |
| FY2025 | Mar 31, 2024 | $3.14M | Jul 10, 2025 |
| FY2024 | Mar 31, 2023 | $4.03M | Jul 15, 2024 |
| FY2023 | Mar 31, 2022 | $3.79M | Jun 29, 2023 |
| FY2022 | Mar 31, 2021 | $3.91M | Jul 13, 2022 |
| FY2021 | Mar 31, 2020 | $4.00M | Jun 23, 2021 |
| FY2020 | Mar 31, 2019 | $4.67M | Jun 12, 2020 |
| FY2019 | Mar 31, 2018 | $5.01M | Jun 14, 2019 |
| FY2018 | Mar 31, 2017 | $4.41M | Jun 14, 2018 |
| FY2017 | Mar 31, 2016 | $4.58M | Jun 14, 2017 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | ($220.2K) | Jul 10, 2025 |
| FY2025 | Mar 31, 2024 | ($691.8K) | Jul 10, 2025 |
| FY2024 | Mar 31, 2023 | ($323.9K) | Jul 15, 2024 |
| FY2023 | Mar 31, 2022 | ($65.6K) | Jun 29, 2023 |
| FY2022 | Mar 31, 2021 | $584.7K | Jul 13, 2022 |
| FY2021 | Mar 31, 2020 | ($198.3K) | Jun 23, 2021 |
| FY2020 | Mar 31, 2019 | ($236.1K) | Jun 12, 2020 |
| FY2019 | Mar 31, 2018 | $335.6K | Jun 14, 2019 |
| FY2018 | Mar 31, 2017 | ($729.3K) | Jun 14, 2018 |
| FY2017 | Mar 31, 2016 | ($880.2K) | Jun 14, 2017 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | ($172.0K) | Jul 10, 2025 |
| FY2025 | Mar 31, 2024 | ($640.8K) | Jul 10, 2025 |
| FY2024 | Mar 31, 2023 | ($302.8K) | Jul 15, 2024 |
| FY2023 | Mar 31, 2022 | ($594.9K) | Jun 29, 2023 |
| FY2022 | Mar 31, 2021 | ($61.6K) | Jul 13, 2022 |
| FY2021 | Mar 31, 2020 | ($156.4K) | Jun 23, 2021 |
| FY2020 | Mar 31, 2019 | ($186.4K) | Jun 12, 2020 |
| FY2019 | Mar 31, 2018 | $395.8K | Jun 14, 2019 |
| FY2018 | Mar 31, 2017 | ($688.2K) | Jun 14, 2018 |
| FY2017 | Mar 31, 2016 | ($708.4K) | Jun 14, 2017 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $593.2K | Jul 10, 2025 |
| FY2025 | Mar 31, 2024 | $621.9K | Jul 10, 2025 |
| FY2024 | Mar 31, 2023 | $816.1K | Jul 15, 2024 |
| FY2023 | Mar 31, 2022 | $918.2K | Jun 29, 2023 |
| FY2022 | Mar 31, 2021 | $569.5K | Jul 13, 2022 |
| FY2021 | Mar 31, 2020 | $748.4K | Jun 23, 2021 |
| FY2020 | Mar 31, 2019 | $779.5K | Jun 12, 2020 |
| FY2019 | Mar 31, 2018 | $842.1K | Jun 14, 2019 |
| FY2018 | Mar 31, 2017 | $1.13M | Jun 14, 2018 |
| FY2017 | Mar 31, 2016 | $1.25M | Jun 14, 2017 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | ($54.9K) | Jul 10, 2025 |
| FY2025 | Mar 31, 2024 | $144.4K | Jul 10, 2025 |
| FY2024 | Mar 31, 2023 | ($861.5K) | Jul 15, 2024 |
| FY2023 | Mar 31, 2022 | ($444.4K) | Jun 29, 2023 |
| FY2022 | Mar 31, 2021 | $219.9K | Jul 13, 2022 |
| FY2021 | Mar 31, 2020 | ($229.5K) | Jun 23, 2021 |
| FY2020 | Mar 31, 2019 | ($127.2K) | Jun 12, 2020 |
| FY2019 | Mar 31, 2018 | $419.4K | Jun 14, 2019 |
| FY2018 | Mar 31, 2017 | $22.9K | Jun 14, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $54.4K | Jul 10, 2025 |
| FY2025 | Mar 31, 2024 | $12.1K | Jul 10, 2025 |
| FY2024 | Mar 31, 2023 | $173.3K | Jul 15, 2024 |
| FY2023 | Mar 31, 2022 | $17.6K | Jun 29, 2023 |
| FY2022 | Mar 31, 2021 | $30.0K | Jul 13, 2022 |
| FY2021 | Mar 31, 2020 | $48.3K | Jun 23, 2021 |
| FY2020 | Mar 31, 2019 | $55.2K | Jun 12, 2020 |
| FY2019 | Mar 31, 2018 | $56.6K | Jun 14, 2019 |
| FY2018 | Mar 31, 2017 | $105.4K | Jun 14, 2018 |
| FY2017 | Mar 31, 2016 | $77.1K | Jun 14, 2017 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $3.67M | Jul 10, 2025 |
| FY2025 | Mar 31, 2024 | $3.81M | Jul 10, 2025 |
| FY2024 | Mar 31, 2023 | $4.13M | Jul 15, 2024 |
| FY2023 | Mar 31, 2022 | $4.79M | Jun 29, 2023 |
| FY2022 | Mar 31, 2021 | $5.66M | Jul 13, 2022 |
| FY2021 | Mar 31, 2020 | $4.74M | Jun 23, 2021 |
| FY2020 | Mar 31, 2019 | $3.43M | Jun 12, 2020 |
| FY2019 | Mar 31, 2018 | $3.25M | Jun 14, 2019 |
| FY2018 | Mar 31, 2017 | $3.07M | Jun 14, 2018 |
| FY2017 | Mar 31, 2016 | $3.81M | Jun 14, 2017 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $2.02M | Jul 10, 2025 |
| FY2025 | Mar 31, 2024 | $1.98M | Jul 10, 2025 |
| FY2024 | Mar 31, 2023 | $1.64M | Jul 15, 2024 |
| FY2023 | Mar 31, 2022 | $2.05M | Jun 29, 2023 |
| FY2022 | Mar 31, 2021 | $2.86M | Jul 13, 2022 |
| FY2021 | Mar 31, 2020 | $2.55M | Jun 23, 2021 |
| FY2020 | Mar 31, 2019 | $1.08M | Jun 12, 2020 |
| FY2019 | Mar 31, 2018 | $1.05M | Jun 14, 2019 |
| FY2018 | Mar 31, 2017 | $1.26M | Jun 14, 2018 |
| FY2017 | Mar 31, 2016 | $1.35M | Jun 14, 2017 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $1.65M | Jul 10, 2025 |
| FY2025 | Mar 31, 2024 | $1.83M | Jul 10, 2025 |
| FY2025 | Mar 31, 2023 | $2.49M | Jul 10, 2025 |
| FY2024 | Mar 31, 2022 | $2.75M | Jul 15, 2024 |
| FY2023 | Mar 31, 2021 | $2.80M | Jun 29, 2023 |
| FY2022 | Mar 31, 2020 | $2.18M | Jul 13, 2022 |
| FY2021 | Mar 31, 2019 | $2.35M | Jun 23, 2021 |
| FY2020 | Mar 31, 2018 | $2.20M | Jun 12, 2020 |
| FY2019 | Mar 31, 2017 | $1.80M | Jun 14, 2019 |
| FY2018 | Mar 31, 2016 | $2.46M | Jun 14, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | ($22.77M) | Jul 10, 2025 |
| FY2025 | Mar 31, 2024 | ($22.55M) | Jul 10, 2025 |
| FY2024 | Mar 31, 2023 | ($21.85M) | Jul 15, 2024 |
| FY2023 | Mar 31, 2022 | ($21.53M) | Jun 29, 2023 |
| FY2022 | Mar 31, 2021 | ($21.46M) | Jul 13, 2022 |
| FY2021 | Mar 31, 2020 | ($22.05M) | Jun 23, 2021 |
| FY2020 | Mar 31, 2019 | ($21.85M) | Jun 12, 2020 |
| FY2019 | Mar 31, 2018 | ($21.61M) | Jun 14, 2019 |
| FY2018 | Mar 31, 2017 | ($21.95M) | Jun 14, 2018 |
| FY2017 | Mar 31, 2016 | ($21.22M) | Jun 14, 2017 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $257.4K | Jul 10, 2025 |
| FY2025 | Mar 31, 2024 | $42.5K | Jul 10, 2025 |
| FY2024 | Mar 31, 2023 | $189.0K | Jul 15, 2024 |
| FY2023 | Mar 31, 2022 | $949.6K | Jun 29, 2023 |
| FY2022 | Mar 31, 2021 | $1.47M | Jul 13, 2022 |
| FY2021 | Mar 31, 2020 | $385.1K | Jun 23, 2021 |
| FY2020 | Mar 31, 2019 | $273.3K | Jun 12, 2020 |
| FY2019 | Mar 31, 2018 | $114.5K | Jun 14, 2019 |
| FY2018 | Mar 31, 2017 | $45.1K | Jun 14, 2018 |
| FY2018 | Mar 31, 2016 | $292.8K | Jun 14, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | 0 | Jul 10, 2025 |
| FY2025 | Mar 31, 2024 | 0 | Jul 10, 2025 |
| FY2024 | Mar 31, 2023 | 0 | Jul 15, 2024 |
| FY2023 | Mar 31, 2022 | 0 | Jun 29, 2023 |
| FY2018 | Mar 31, 2018 | 0 | Jun 14, 2018 |
| FY2018 | Mar 31, 2017 | 0 | Jun 14, 2018 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | 0 | Jul 10, 2025 |
| FY2025 | Mar 31, 2024 | 0 | Jul 10, 2025 |
| FY2024 | Mar 31, 2023 | 0 | Jul 15, 2024 |
| FY2023 | Mar 31, 2022 | 0 | Jun 29, 2023 |
| FY2018 | Mar 31, 2018 | 0 | Jun 14, 2018 |
| FY2018 | Mar 31, 2017 | 0 | Jun 14, 2018 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | 11.88M | Jul 10, 2025 |
| FY2025 | Mar 31, 2024 | 11.86M | Jul 10, 2025 |
| FY2024 | Mar 31, 2023 | 11.77M | Jul 15, 2024 |
| FY2023 | Mar 31, 2022 | 11.72M | Jun 29, 2023 |
| FY2022 | Mar 31, 2021 | 11.58M | Jul 13, 2022 |
| FY2021 | Mar 31, 2020 | 11.58M | Jun 23, 2021 |
| FY2020 | Mar 31, 2019 | 11.56M | Jun 12, 2020 |
| FY2019 | Mar 31, 2018 | 10.68M | Jun 14, 2019 |
| FY2018 | Mar 31, 2017 | 10.68M | Jun 14, 2018 |
| FY2017 | Mar 31, 2016 | 10.67M | Jun 14, 2017 |